Jerome Benz, DO
Ophthalmology · York, PANPI 1104813468
Payments from drug & device makers
Across 49 payments — averaging $24.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$281
- Alcon$246
- AbbVie$179
- Glaukos Corporation$127
- Bausch & Lomb Americas Inc.$69
- Oyster Point Pharma, Inc.$61
- plus $243 from 11 others
What the payments were for
- Consulting fees$20017%
- Food & beverage$98982%
- Gifts$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 3 | $281 |
| Alcon | 14 | $246 |
| AbbVie(2 entities) | 8 | $179 |
| Glaukos Corporation | 4 | $127 |
| Bausch & Lomb Americas Inc. | 4 | $69 |
| Oyster Point Pharma, Inc. | 3 | $61 |
| Novartis | 3 | $47 |
| Tarsus Pharmaceuticals, Inc. | 1 | $29 |
| Rxsight Inc | 1 | $26 |
| Shire North American Group Inc | 1 | $24 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $22 |
| Ivantis, Inc | 1 | $18 |
| Biotissue Holdings Inc. | 1 | $18 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| Sight Sciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXTENZA$600
How this compares
$1,206 in reported general payments places this provider in the 45th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 351 | $8,847 |
| BromsiteBromfenac Sodium | 14 | $3,521 |
| Bromfenac Sodium | 11 | $1,547 |
| Atropine Sulfate | 59 | $945 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 16 | $95 |
| Latanoprost | 23 | $41 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in York
- Denise ViscoYork$242K
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
- Erik KrugerKingston$3M
- Sunir GargPlymouth Meeting$2M
- Allen ChiangPlymouth Meeting$1.6M
- Julia HallerPhiladelphia$1.5M
- Mitchell FinemanPlymouth Meeting$1.3M
- Allen HoPlymouth Meeting$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.